Solubilisierung stark lipophiler Arzneistoffe in lipidhaltige ...

Literaturverzeichnis
101. Andersson, S., Molecular genetics of androgenic 17 beta-hydroxysteroid dehydrogenases,
J. Steroid Biochem. Mol. Biol. 55 (1995) 533-534.
102. Akinola, L. A., Poutanen, M., und Vihko, R., Cloning of rat 17 beta-hydroxysteroid dehydrogenase
type 2 and characterization of tissue distribution and catalytic activity of rat type 1 and type 2
enzymes, Endocrinology 137 (1996) 1572-1579.
103. Eik-Nes, K. B., Stenstad, P., und Lofthus, R., Metabolism in vitro of testosterone (T) to 17 betahydroxy-5
alpha-androstane-3-one (DHT) and 5 alpha-androstane-3 alpha,17 beta-diol (3 alpha)
by the 800 g supernatant fraction of ileum from rats, J. Steroid Biochem. 19 (1983) 683-686.
104. Stenstad, P. und Eik-Nes, K. B., In vitro metabolism of testosterone to 17 beta-hydroxy-5 alphaandrostane-3-one
and 5 alpha-androstane-3 alpha, 17 beta-diol by the rat intestine, J. Steroid
Biochem. 17 (1982) 401-406.
105. Buur, A. und Mork, N., Metabolism of testosterone during in vitro transport across CACO-2 cell
monolayers: evidence for beta-hydroxysteroid dehydrogenase activity in differentiated CACO-2
cells, Pharm. Res. 9 (1992) 1290-1294.
106. Oppermann, U. C. und Maser, E., Characterization of a 3 alpha-hydroxysteroid dehydrogenase/
carbonyl reductase from the gram-negative bacterium Comamonas testosteroni, Eur. J.
Biochem. 241 (1996) 744-749.
107. Laube, B., Winkler, S., Ladstetter, B., Scheller, T., und Schwarz, L. R., Establishment of a novel in
vitro system for studying the interaction of xenobiotic metabolism of liver and intestinal
microflora, Arch. Toxicol. 74 (2000) 379-387.
108. Shinohara, Y., Baba, S., und Kasuya, Y., Absorption, metabolism, and excretion of oral
testosterone in humans by mass fragmentography, J. Clin. Endocrinol. Metab. 51 (1980) 1459-
1462.
109. Pacifici, G. M., D'alessandro, C., Gucci, A., und Giuliani, L., Sulphation of the heterocyclic amine
1,2,3,4-tetrahydroisoquinoline in the human liver and intestinal mucosa: interindividual variability,
Arch. Toxicol. 71 (1997) 477-481.
110. Pacifici, G. M., Temellini, A., Castiglioni, M., D'alessandro, C., Ducci, A., und Giuliani, L.,
Interindividual variability of the human hepatic sulphotransferases, Chem. Biol. Interact. 92
(1994) 219-231.
111. Matsumoto, A. M., The testis and male function, In: Wyngaarden, J. B., Smith, L. H., und Bennet,
J. C. [Hrsg.], Cecil Textbook of medicine, WB Saunders, Philadelphia, USA, (1992), S. 1333.
112. Mutschler, E., Geisslinger, G., Kroemer, H. K. und Schäfer-Korting, M., Mutschler Arzneimittelwirkungen,
(8. Auflage), Wiss. Verl.-Ges. mbH (WVG), Stuttgart, DE, (2001), S. 450.
113. van Asperen, J., van Tellingen, O., und Beijnen, J. H., The pharmacological role of P-glycoprotein
in the intestinal epithelium, Pharmacol. Res. 37 (1998) 429-435.
114. Borst, P., Zelcer, N., und van Helvoort, A., ABC transporters in lipid transport, Biochim. Biophys.
Acta 1486 (2000) 128-144.
115. Borst, P., Evers, R., Kool, M., und Wijnholds, J., The multidrug resistance protein family,
Biochim. Biophys. Acta 1461 (1999) 347-357.
116. Germann, U. A., Pastan, I., und Gottesman, M. M., P-glycoproteins: mediators of multidrug
resistance, Semin. Cell Biol. 4 (1993) 63-76.
117. Katoh, M., Nakajima, M., Yamazaki, H., und Yokoi, T., Inhibitory effects of CYP3A4 substrates and
their metabolites on P-glycoprotein-mediated transport, Eur. J. Pharm. Sci. 12 (2001) 505-513.
118. Oka, A., Oda, M., Saitoh, H., Nakayama, A., Takada, M., und Aungst, B. J., Secretory transport of
methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells, Biol. Pharm. Bull. 25
(2002) 393-396.
119. Taeuber, U., Absolute bioavailability of testosterone after oral administration of testosteroneundecanoate
and testosterone. Reply to comments, Eur. J. Drug Metab. Pharmacokinet. 12
(1987) 226.
cxiv